| Role |
Name |
Disclosure |
Details |
| Author | Sean P Bush, MD, FACEP, Professor of Emergency Medicine, Envenomation Specialist, Department of Emergency Medicine, Loma Linda University School of Medicine; Consulting Staff, Loma Linda University Medical Center | Protherics Fougera Rare Disease Therapeutics Bioclon | Details | | Coauthor | Eric J Lavonas, MD, FACEP, Associate Director, Rocky Mountain Poison and Drug Center; Assistant Professor, University of Colorado School of Medicine | Nothing to disclose | Details | | Medical Editor | Robert Norris, MD, Chief, Associate Professor, Department of Surgery, Division of Emergency Medicine, Stanford University Medical Center | Nothing to disclose | Details | | Pharmacy Editor | John T VanDeVoort, PharmD, ABAT, Director of Pharmacy, Sacred Heart Hospital | Nothing to disclose | Details | | Managing Editor | David Eitel, MD, MBA, Associate Professor, Department of Emergency Medicine, York Hospital | Nothing to disclose | Details | | CME Editor | John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center | Nothing to disclose | Details | | Chief Editor | Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School | eMedicine.com, Inc. | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| David Eitel, Managing Editor |
The contributor discloses no conflict of interest. |
|